Clinical Core

临床核心

• 批准号: 10746569
• 负责人: Javier A. Neyra
• 金额: $ 30.51万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2028-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10746569
• 关键词: Acute Renal Failure with Renal Papillary Necrosis; Address; Basic Science; Benchmarking; Big Data; Bioinformatics; Biological Specimen Banks; COVID-19; Center Core Grants; Classification; Clinical; Clinical Data; Clinical Research; Clinical Sciences; Clinical Trials; Clinical and Translational Science Awards; Collaborations; Communication; Communities; Consultations; Data; Databases; Development; Electronic Health Record; Epidemiologic Monitoring; Epidemiology; Female; Funding; Goals; Healthcare; Heterogeneity; Human; Human Resources; Incidence; Individual; Industry; Infrastructure; Institution; Kidney; Kidney Diseases; Link; Medicine; Methodology; Methods; Outcome; Pathway interactions; Patient-Focused Outcomes; Patients; Peer Review; Peptides; Phenotype; Policies; Public Health; Publications; Registries; Research; Research Personnel; Resource Development; Resources; Risk; Risk Factors; Science; Structure; Technology; Translating; Translational Research; Translations; United States National Institutes of Health; Validation; base; biobank; bioinformatics resource; bioinformatics tool; clinical center; clinical data repository; clinical database; computing resources; data acquisition; data mining; data resource; design; digital; electronic health data; federated learning; innovation; interest; male; novel; personalized medicine; pre-clinical; preclinical evaluation; preclinical imaging; programs; response; small molecule; success; therapeutic target; tool; treatment effect

Project Summary Acute kidney injury (AKI) is a public health concern with direct impact on clinical and patient-centered outcomes, and healthcare resource utilization and policy. Recognizing the paucity of breakthrough discoveries in AKI and the growing burden of this condition, the UAB-UCSD O’Brien Clinical Core (Core A) is designed to reduce the barriers for investigators to conduct effective clinical and translational research by providing a robust infrastructure to promote collaborative projects across pre-clinical, clinical and industry researchers. Core A will provide multifaceted consultation through a customized Project Gateway, access to clinical databases, available biorepositories, and novel bioinformatics and computational technologies such as the U-BRITE and Nightingale collaborative digital workspaces in partnership with the Clinical and Translational Science Awards (CTSA) programs at both institutions for the harmonization and interrogation of big data with a focus on personalized medicine in AKI. Specifically, Core A will facilitate collaborative digital workspaces for electronic health record (EHR) data acquisition, transformation, validation, and interrogation. The overarching goal is to catalyze the translation of bench discoveries to applications that impact human AKI. The Specific Aims are structured as follows. In Aim 1, we will provide access to clinical data of patients at risk for or with AKI and consultation for their use. Specifically, we will provide access to curated clinical data from prior clinical studies hosted by Core A (Aim 1A) and provide access to new harmonized real-world data from the EHR to support epidemiological surveillance of AKI (e.g., AKI incidence, risk factors and outcomes) and novel clinical research, including but not limited to AKI risk-classification, sub-phenotyping, and simulated trials (Aim 1B). In Aim 2, we will provide access to biospecimens of patients at risk for or with AKI and consultation for their use. Specifically, we will provide access to biospecimens from prior studies hosted by Core A (Aim 2A). In Aim 2B we will provide a novel platform to link biospecimens of patients at risk for or with AKI with EHR data. Core A will have dynamic communications and collaborations with the Pre-Clinical Core, the Resource Development Core, and the O’Brien Kidney Consortium. In this U54 application, we will build upon our expertise and established successes demonstrated through our currently funded O’Brien Center P30 award. Given our commitment and expertise, we are confident that Core A will provide innovative resources to the growing research community interested in AKI-related research.

项目摘要 急性肾脏损伤（AKI）是公共卫生的关注，直接影响临床和以患者为中心的结果， 以及医疗保健资源利用和政策。认识到AKI中突破性发现的匮乏和 UAB-UCSD O’Brien临床核心（核心A）旨在减少这种情况的日益严格的燃烧。 调查人员通过提供强大的障碍进行有效的临床和翻译研究 跨临床，临床和行业研究人员促进协作项目的基础设施。核心遗嘱 通过定制的项目网关，访问临床数据库，提供多方面的咨询， 可用的生物库以及新颖的生物信息学和计算技术，例如U-Brite和 与临床和转化科学合作的夜莺合作数字工作区 两个机构的奖项（CTSA）计划，以重点统一和审问大数据 关于AKI的个性化医学。具体而言，核心A将有助于电子的协作数字工作区 健康记录（EHR）数据采集，转型，验证和审讯。总体目标是 催化基准发现向影响人类AKI的应用的翻译。具体目的是 结构如下。在AIM 1中，我们将提供访问有AKI或有AKI风险或患有AKI的患者的临床数据 咨询使用。具体而言，我们将提供先前临床研究的精选临床数据的访问 由Core A（AIM 1A）托管，并提供来自EHR的新统一现实数据的访问权限 AKI的流行病学监测（例如AKI事件，风险因素和结果）和新的临床研究， 包括但不限于AKI风险分类，子表型和模拟试验（AIM 1B）。在AIM 2中，我们 将提供有风险或患有AKI风险的患者的生物测量，并咨询他们的使用。具体来说， 我们将提供来自Core A（AIM 2A）的先前研究的生物测量访问权限。在AIM 2B中，我们将提供 一个新的平台，将具有AKI或与EHR数据的风险或患有AKI风险的患者的生物传染性联系起来。核心A将具有动态 与临床前核心，资源开发核心和 奥布莱恩肾脏财团。在此U54应用程序中，我们将基于我们的专业知识并确定成功 通过我们目前资助的O'Brien Center P30奖展示。鉴于我们的承诺和专业知识 我们有信心核心A将为不断增长的研究社区提供创新的资源 与AKI相关的研究。